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The principle functions of neuroinﬂammation are to limit tissue damage and promote tissue repair in
response to pathogens or injury. While neuroinﬂammation has utility, pathophysiological inﬂammatory
responses, to some extent, underlie almost all neuropathology. Understanding the mechanisms that
control the three stages of inﬂammation (initiation, propagation and resolution) is therefore of critical
importance for developing treatments for diseases of the central nervous system. The purinergic
signaling system, involving adenosine, ATP and other purines, plus a host of P1 and P2 receptor subtypes,
controls inﬂammatory responses in complex ways. Activation of the inﬂammasome, leading to release of
pro-inﬂammatory cytokines, activation and migration of microglia and altered astroglial function are key
regulators of the neuroinﬂammatory response. Here, we review the role of P1 and P2 receptors in
mediating these processes and examine their contribution to disorders of the nervous system. Firstly, we
give an overview of the concept of neuroinﬂammation. We then discuss the contribution of P2X, P2Y and
P1 receptors to the underlying processes, including a discussion of cross-talk between these different
pathways. Finally, we give an overview of the current understanding of purinergic contributions to
neuroinﬂammation in the context of speciﬁc disorders of the central nervous system, with special
emphasis on neuropsychiatric disorders, characterized by chronic low grade inﬂammation or maternal
inﬂammation. An understanding of the important purinergic contribution to neuroinﬂammation un-
derlying neuropathology is likely to be a necessary step towards the development of effective
interventions.
© 2015 Elsevier Ltd. All rights reserved.Contents
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neuroinﬂammation
The term ‘inﬂammation’ was coined by Celsus around the 1st
century BC, deﬁned by four cardinal signs; tumor, rubor, calor and
dolor (Celsus, 1478) (i.e. oedema, redness, increased temperature
and pain in the affected tissue) with a ﬁfth sign, loss of function,
attributed to Galen. By the identiﬁcation of underlying molecular
and cellular mechanisms, inﬂammation now assumes a substan-
tially wider meaning, as a complex biological response to harmful
stimuli, composed of three phases: initiation, propagation and
resolution (Lister et al., 2007). While the principle functions of
inﬂammation are to limit tissue damage and promote tissue repair
(Nathan, 2002), inappropriate inﬂammatory responses, particularly
when chronic, can lead to toxicity and cell loss (Hauss-Wegrzyniak
et al., 2002).
The central nervous system (CNS), separated from the periphery
by a specialized blood brain barrier (BBB) has long been considered
an ‘immuno-privileged’ region (Carson et al., 2006), protected from
systemic immune and inﬂammatory responses to pathology or
injury. Behind the protection of the BBB, however, CNS-speciﬁc
immune effector cells, particularly microglia (Streit et al., 2004),
mediate neuroinﬂammatory responses to insult in response to a
variety of triggers, including toxic metabolites, autoimmunity
(Gendelman, 2002) or via the detection of pathogens or endoge-
nous damage-associated molecular patterns (PAMPs and DAMPs)
released in response to CNS damage, such as traumatic brain injury
(Bernier, 2012). The outcome of a neuroinﬂammatory response
depends, to a large extent, on its severity and duration
(Vivekanantham et al., 2015), but pathological neuroinﬂammation,
promoting apoptosis and necrosis and inﬂuencing the synaptic and
intrinsic membrane properties of neurons (Yirmiya and Goshen,
2011), contributes to a host of CNS pathologies. A central role for
neuroinﬂammation has been reported for primary or secondary
neurodegenerative diseases, such as Alzheimer's disease (AD),
Parkinson's disease (PD), multiple sclerosis (SM) amyotrophic
lateral sclerosis (ALS), Huntington's disease, stroke and epilepsy
(Frank-Cannon et al., 2009). Neuroinﬂammation has also been
recognized as a pathological factor in psychiatric mood disorders,
characterized by chronic mild neuroinﬂammation (Najjar et al.,
2013), and developmental neuropsychiatric disorders, such as
schizophrenia and autism (Meyer, 2013).
The main cellular effectors of neuroinﬂammation are astrocytes
and microglia, as well as perivascular monocytes and macrophages
invading to sites of insult from the circulation (Yamasaki et al.,
2014). In addition, neurogenic neuroinﬂammation, the direct
contribution of neuronal activity, is a unique feature of the nervous
system (Xanthos and Sandkuhler, 2014). Chronic neuro-
inﬂammation involves the sustained activation of glial cells, chronic
release of pro-inﬂammatory cytokines, increased permeability of
the BBB and recruitment of systemic immune effector cells into the
CNS (O'Callaghan et al., 2008).
Neuroinﬂammatory cascades rely on the activation of an
inﬂammasome, a protein complex, consisting of caspase-1,
apoptosis-associated speck-like protein (ASC) and nod-like recep-
tor protein (NLRP1 or NLRP3) (Martinon et al., 2002). The inﬂam-
masome is the principle source of mature proinﬂammatoryPlease cite this article in press as: Beamer, E., et al., Purinergic mechan
Neuropharmacology (2015), http://dx.doi.org/10.1016/j.neuropharm.2015cytokine IL-1b, with caspase-1 activity necessary for the proteolytic
cleaving of proeIL-1b (Gross et al., 2011). While NLRP inﬂamma-
somes are activated by the recognition of PAMPs or DAMPs (Bernier,
2012), the identiﬁcation of host-derived DAMPs has become a
major project, necessary for uncovering the pathway from insult to
pathology.
The NLRP3 inﬂammasome and its downstream pathway has
been recognized as a central mediator of systemic inﬂammation
and a key mechanistic link between psychological stress and the
emergence of depression and other psychiatric illnesses (Iwata
et al., 2013). Much evidence has accumulated that ATP, found at
higher extracellular concentrations following insult, potently in-
duces NLRP-mediated IL-1b processing (Burnstock, 2008) and that
its metabolite, adenosine, is also heavily involved in themodulation
of this signaling pathway. ATP and other nucleotides, such as UTP
are released from induced cells and provide “ﬁnd-me” and “eat-
me” signals contributing to different phases of neuroinﬂammation
by activating purinoceptors (Di Virgilio et al., 2009). Purinergic
involvement in neuroinﬂammatory processes include the media-
tion of early events such as chemotaxis, microglia activation and
the secretion of pro-inﬂammatory cytokines, phagocytosis, reactive
astrogliosis and repair mechanisms such as neurogenesis.
Here we review the current understanding of the role of puri-
nergic signaling in mediating the three phases of inﬂammation, the
effect of the neuroinﬂammatory response on neuronal survival and
functionality and the etiology and progression of CNS disease.
Because the role of purinergic mechanisms in neurodegenerative
diseases, such as AD, PD, SM, ALS and neuropathic pain is widely
covered by other articles in this special issue; see (Burnstock, 2015),
we will emphasize selected aspects which highlight the purinergic
regulation of astrocytic and microglial cellular neuroinﬂammatory
responses and their peculiar role in psychiatric disorders. Further
elucidation of the participation of purinergic receptors in neuro-
inﬂammation will lead to a better of understanding of its role in
neuropathology and may also pave the way towards more targeted
and innovative therapies to combat CNS disorders.1.1. The role of P2X receptors in neuroinﬂammation
P2X receptors are ligand-gated cation channels, rendered
permeable to Naþ, Kþ and Ca2þ upon the binding of ATP
(Abbracchio et al., 2009). Seven P2X subunits are expressed in the
brain (P2X1-7), with P2X1-5 combining to form functional re-
ceptors with a heterotrimeric or homotrimeric quaternary struc-
ture, P2X6 forming only as a part of heterotrimeric receptors and
P2X7 forming only homotrimers (North, 2002). Each combination
of subunits forms a functional channel with different afﬁnities for
ATP and different desensitization dynamics conferring a variety in
physiological responses to ATP; while P2X1 and P2X3 receptors
desensitize within hundreds of milliseconds, P2X2 and P2X4 re-
ceptors desensitize an order of magnitude slower, and P2X7 re-
ceptors show very little desensitization, even over minutes (North
and Jarvis, 2013). Both levels of subunit expression and receptor
composition vary according to cell type and brain region. ATP-
afﬁnity and receptor function are also modulated by phosphory-
lation state and a host of allosteric and non-allosteric modulators,
including heavy metals and reactive oxygen species (Coddou et al.,isms in neuroinﬂammation: An update from molecules to behavior,
.09.019
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Much evidence exists for changes in P2X subtype expression in
neuroinﬂammatory conditions in various in vitro and in vivo
models. For instance, early studies reported that P2X1 was strongly
and transiently upregulated following ischemic insult in the hip-
pocampus (Cavaliere et al., 2003), while P2X2 and P2X4 are upre-
gulated in the dentate gyrus following oxygen and glucose
deprivation in an organotypic hippocampal slice culture. Another
study revealed an upregulation of P2X1 and P2X2 at the site of
neurodegeneration following axotomy (Viscomi et al., 2004). P2X4
is expressed at increased concentrations in response to tissue injury
following spinal cord injury (Schwab et al., 2005), traumatic brain
injury (Zhang et al., 2006) and in spinal cord microglia following
peripheral nerve injury (Tsuda et al., 2003; Ulmann et al., 2008).
After stabwound injury, P2X1 and P2X7 receptor immunoreactivity
was observed on astrocytes that were previously absent (Franke
et al., 2004). Cerebellar lesions produce up-regulation of P2X1
and P2X2 receptors in precerebellar nuclei (Florenzano et al., 2002).
The majority of these studies, however, lack evidence for a causa-
tive relationship between P2X receptor activation and
neuroinﬂammation.
Of the seven P2X subtypes, by far the strongest body of evidence
for involvement in mediating neuroinﬂammation exists for P2X7
(Lister et al., 2007). Gene-linking and epidemiological studies have
implicated P2X7 in a host of CNS diseases (Hansen et al., 2008; Ursu
et al., 2014). In vivo studies, meanwhile, have been used to
demonstrate the involvement of the P2X7 receptor in activating the
inﬂammasome in a broad variety of rodent disease models,
including cerebral ischemia (Kuan et al., 2015), epilepsy (Engel
et al., 2012), Parkinson's disease (Marcellino et al., 2010), Alz-
heimer's disease (Diaz-Hernandez et al., 2012), depression and
anxiety (Basso et al., 2009) and multiple sclerosis (Sharp et al.,
2008). Systemic administration of bacterial lipopolysaccharide
(LPS) markedly increases the expression of P2X7 receptors in the
CNS (Choi et al., 2007), offering a mechanism for changes in CNS
function in response to systemic infection.
A couple of features of the P2X7 receptor make it an optimal
mediator of cellular responses to pathology. Firstly, the low-afﬁnity
of the receptor for ATP and its slow desensitization dynamics mean
that it is unresponsive to micromolar ﬂuctuations in extracellular
ATP concentrations. This allows ATP signaling to function in
different ways at different concentrations, with phasic micromolar
ATP signaling operating via other P2X receptors to modulate a
number of physiological pathways, e.g. functioning as a neuro-
modulator at glutamatergic synapses (Gu and MacDermott, 1997),
while millimolar concentrations, released into the extracellular
milieu in response to injury, can act, via P2X7, as a DAMP, initiating
neuroinﬂammatory cascades (Fiebich et al., 2014). Secondly, the
pore-forming functionality of the P2X7 receptor facilitates the
release of larger hydrophilic molecules, up to 900 Da (Surprenant
et al., 1996), a process which may be important for initiating neu-
roinﬂammation. Indeed, the formation of the P2X7 receptor pore
seems to be necessary for the role of the molecule in activating the
inﬂammasome (Monif et al., 2009).
The principle function of the inﬂammasome is the cleavage, by
the protease, caspase-1, of precursor interleukin molecules into the
forms, IL-1b and IL-18 and the subsequent release of these pro-
inﬂammatory cytokines into the extracellular space (Watanabe
et al., 2007). This process involves three steps: ﬁrstly, synthesis of
precursor molecules, e.g. pro-IL-1b, secondly, the cleavage of the
precursors into the active form, and thirdly, the release of the active
form into the extracellular milieu. Synthesis of precursors is upre-
gulated via the activation of toll-like receptors (TLRs) (He et al.,
2013). Subsequently, NLRP1 or NLRP3 inﬂammasomes activated
by PAMPs or DAMPs, induce the protease, caspase-1, which thenPlease cite this article in press as: Beamer, E., et al., Purinergic mechan
Neuropharmacology (2015), http://dx.doi.org/10.1016/j.neuropharm.2015cleaves pro-IL-1b into the active form (alongside IL-18). Thirdly,
release of the active pro-inﬂammatory cytokines requires loading
of the inﬂammasome complex into the secretory lysosome, or the
formation of membrane blebs (Di Virgilio et al., 2009; Ferrari et al.,
2006). ATP functions as a DAMP, via P2X7, activating the inﬂam-
masome and caspase-1 (Deplano et al., 2013) and is also involved in
cytokine release, with modulation of cell membrane Kþ perme-
ability being a key step in both processes. In this way, TLRs load the
gun, while P2X7 receptors pull the trigger (Fig. 1).
P2X7 receptor activation of the inﬂammasome in response to
high extracellular concentrations of ATP seems to rely primarily on
Kþ efﬂux through the cell membrane (Bernier, 2012; Lister et al.,
2007). P2X7 receptor activation leads to an increase in perme-
ability to Kþ, either directly through the P2X7 receptor pore, or
through the opening of pannexin-1 hemichannels (Panx1).
Reduced intracellular Kþ concentration is the primary trigger of
caspase-1 activation (Munoz-Planillo et al., 2013). While some re-
ports indicate that Panx1 channel opening is an obligatory part of
both NLRP1 and NLRP3 inﬂammasome activation (de Rivero Vaccari
et al., 2008; Pelegrin and Surprenant, 2006; Silverman et al., 2009),
other groups have reported P2X7 receptor-induced IL-1b release,
independent of Panx1 (Pelegrin et al., 2008; Qu et al., 2011). A
further study postulated that Panx1 is responsible for the release of
ATP from dying cells, upstream of P2X7 activation in the signaling
cascade (Dahl and Keane, 2012). Alternatively, Panx1 hemichannels
may open in response to an increase in extracellular Kþ as a result
of P2X7 pore opening (Bernier, 2012), acting to amplify Kþ efﬂux.
P2X7 receptors are found in highest concentrations on micro-
glia, but are also expressed on astrocytes, oligodendrocytes and
neurons, particularly at presynaptic terminals (Weisman et al.,
2012). P2X7 receptor expression on different cell types, upregu-
lated in response to CNS insult, combines to mediate a neuro-
inﬂammatory response. ATP-activated microglia are key regulators
of the neuroinﬂammatory response, releasing IL-1b in response to
insult (Ferrari et al., 1997; Silverman et al., 2009), adopting an
activated morphology, proliferating and migrating to the site of
insult, to form an inﬂammatory focus. It has been demonstrated
that P2X7 receptor overexpression is both necessary and sufﬁcient
to drive these processes (Monif et al., 2009). Other studies (de
Rivero Vaccari et al., 2012), however, revealed the importance of
IL-1b release from neurons, while Silverman et al. (Silverman et al.,
2009) report that in neurons, high extracellular Kþ can activate the
inﬂammasome via Panx1-dependent efﬂux. These latter data
indicate that neurons may be the ﬁrst site of IL-1b release following
an insult (Fig. 1).
Further, P2X7 receptor stimulation of enteric neurons elicits a
direct release of ATP onto glia through Panx1 (Gulbransen et al.,
2012). By way of this paracrine signaling, the P2X7 receptor can
function as a gatekeeper between glia and neurons to regulate in-
ﬂammatory cascades (Browne, 2013). Astrocytic P2X7 receptor
expression has also been implicated in contributing to the inﬂam-
matory response, with the activation of astroglial P2X7 receptors
leading to a neurotoxic phenotype in a model of ALS (Gandelman
et al., 2010), while following trauma, astroglial P2X7 receptor
activation leads to upregulation of the chemokine, monocyte che-
moattractant protein-1 (MCP-1) and, subsequently an increased
invasion of systemic immune cells into the site of insult (Panenka
et al., 2001).
As previously described, there is plenty of evidence for changes
in P2X receptor expression during neuroinﬂammation, but other
than P2X7, there is little evidence that these receptors mediate the
process. Evidence is accumulating, however, that P2X4 receptors
may also play a role. P2X4 knockouts show less microglial activa-
tion and the loss of the prostaglandin E2-mediated inﬂammatory
pathway (Ulmann et al., 2010). P2X4 receptors, similarly to P2X7,isms in neuroinﬂammation: An update from molecules to behavior,
.09.019
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ion efﬂux and subsequently inﬂammasome activation (Fiebich
et al., 2014). Interestingly, this process appears to be Panx1-
independent (Bernier, 2012). A recent study showed that P2X4
knockout mice displayed impaired inﬂammasome activation
resulting in a decrease in extracellular IL-1b and reduced inﬁltra-
tion of neutrophils and monocyte-derived M1 macrophages
following spinal cord injury (de Rivero Vaccari et al., 2012). Further,
Compan et al. (2012) report that receptors made up of P2X2 and
P2X5 subunits, which are expressed in speciﬁc neuronal pop-
ulations, also show an ability to form a P2X7 receptor-like dilated
pore, suggesting that these receptors may also function asATP 
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inﬂammasome activation by distinct P2X receptorsmight represent
responses to insults of different intensity. While the P2X4 receptor
may act as an initial trigger, the P2X7 receptor, in concert with
Panx1, may amplify the signal (Fig. 2).1.2. The role of P2Y receptors in neuroinﬂammation
P2Y receptors are metabotropic receptors activated by adenine
and uridine nucleotides and belong to the superfamily of G protein
coupled receptors. So far eight subtypes of P2Y subfamily have been2X7R 
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which are divided into two subgroups i.e. those coupled by Gq
(P2Y1, P2Y2, P2Y4, P2Y6, P2Y11) and those coupled by Gi (P2Y12,
P2Y13 and P2Y14) (Pelegrin et al., 2008; Qu et al., 2011). Like P2X,
P2Y receptors also differ in their agonist binding proﬁles, with one
group speciﬁc to adenine nucleotides (P2Y1, P2Y12, P2Y13), another
group (P2Y2 and rodent P2Y4) activated by both adenine and uri-
dine nucleotides, a third group speciﬁc to uridine nucleotides
(human P2Y4 and P2Y6) and P2Y14 activated by UDP-glucose (Jokela
et al., 2014). All known subtypes of P2Y receptors are expressed in
the CNS with variable distribution among different cell types (i.e.
neurons, astrocytes, microglia, oligodendrocytes) (Burnstock and
Knight, 2004). These receptors are activated during pathological
conditions and participate in neuroinﬂammation in many different
ways. The majority of data are derived from cell culture models of
neuroinﬂammation and are yet to be replicated in in vivo assays
using speciﬁc probes to identify receptor subtypes (e.g. gene deﬁ-
cient mice, shRNA). Nevertheless, we highlight here the most
important functions attributed to P2Y receptors in the regulation of
neuroinﬂammation.
P2Y1 receptors are expressed by neurons, astrocytes, oligoden-
drocytes and microglia and their primary postulated function is
neuromodulation. In addition a recent study found that P2Y1 re-
ceptors expressed on astrocytes can be activated under conditions
of oxidative stress, stimulating the release of IL-6. In this way, P2Y1
acts as a gatekeeper of astrocyte-mediated neuroprotection (Fujita
et al., 2009).
Uridine nucleotide-sensitive P2Y2 receptors are expressed by
neurons, astrocytes and microglia and a growing number of studies
implicate a role in neuroinﬂammation. Uniquely amongst the P2Y
family, these receptors possess a consensus integrin-binding motif
which interacts with avB3/5 intergin, regulating actin polymeri-
zation and cytoskeletal rearrangements through the Rac/Rho
pathways (Weisman et al., 2012). P2Y2 receptors are upregulated in
animal models of inﬂammation and, interestingly, P2X7 receptor
activation on astrocytes and microglia act as a signal to upregulate
P2Y2 receptors through the release of the proinﬂammatory cyto-
kine IL-1b. The activation of P2Y2 confers neuroprotection, partic-
ularly in AD, through several pathways: the promotion of neurite
outgrowth, increases in cell motility, the processing of non-
amyloidogenic APP and enhancement of phagocytosis and degra-
dation of the Ab peptide (Erb et al., 2015; Kim et al., 2012;Weisman
et al., 2012). Using a TgCRND8mouse model of AD, Ajit, et al. (2014)
demonstrated both that P2Y2 expression is enhanced in concert
with the AD phenotype, and that genetic deletion of P2Y2 enhances
early AD pathology. In addition P2Y2 receptors expressed on sat-
ellite glia participate in the sensitization leading to trigeminal pain
(Magni et al., 2015).
In comparisonwith P2Y2 receptors, the data on the involvement
of P2Y4 receptors in neuroinﬂammation is relatively sparse.
Although the expression of P2Y4 receptors in microglia is well
documented, e.g. (Bianco et al., 2005; Fumagalli et al., 2003), the
lack of speciﬁc tools to probe the receptor mean that a full under-
standing of its role remains elusive. In addition to P2Y2 and P2Y4,
P2Y6 receptors are also activated by uridine nucleotides, particu-
larly UDP. These receptors regulate the phagocytic activity of
microglia in vivo (Inoue, 2007). This process may be important
under conditions of neuronal damage. UDP, leaking out from
damaged hippocampal cells facilitates the uptake of cellular debris
by microglia in a P2Y6 -dependent manner (Koizumi et al., 2007).
Because there is no rodent orthologue of the P2Y11 receptor, our
knowledge regarding its role in neuroinﬂammation is limited.
While P2Y11 mRNA can be found in the nervous system (Burnstock
and Knight, 2004), and these receptors are expressed on human
immunocytes and regulate neurotrophil apoptosis (Communi et al.,Please cite this article in press as: Beamer, E., et al., Purinergic mechan
Neuropharmacology (2015), http://dx.doi.org/10.1016/j.neuropharm.20151999; Vaughan et al., 2007), a potential immunomodulatory role in
the CNS may also be hypothesized.
P2Y12 receptors are Gi-coupled receptors and well-known as the
target site of widely used antithrombotic drugs such as clopidogrel
or ticagrelor, and are therefore of considerable interest to cardio-
vascular medicine. Activation of P2Y12 receptors by ADP leads to
rapid platelet aggregation. The inhibition of this effect is utilized in
the clinic to prevent myocardial infarction and stroke. P2Y12 re-
ceptors, expressed on platelets, regulate various forms of inﬂam-
mation and could either improve or worsen the scenario (Liverani
et al., 2014a). In the CNS, P2Y12 receptors are expressed on astro-
cytes, oligodendrocytes and the resting, ramiﬁed microglia
executing surveillant functions (Amadio et al., 2014; Franke et al.,
2004).
The very ﬁrst report indicating that P2Y12 receptors regulate the
reactivity of microglia showed that P2Y12 receptors are instru-
mental for microglial chemotaxis in response to local brain injury.
The expression of P2Y12 decreases during the morphological
change from the resting ramiﬁed to activated amoeboid state
associated with microglial activation (Haynes et al., 2006). Recent
investigation using in vivo two photon microscopy technologies
conﬁrmed a key role for P2Y12 receptors in the regulation of
microglial dynamics in response to other alarm signals. For
example, during epileptic seizures, excess glutamate is released,
which promotes microglial process extension towards the site of
damage. This process involves the activation of neuronal NMDA
receptors, calcium inﬂux, subsequent ATP release, and the activa-
tion of P2Y12 receptors (Eyo et al., 2014).
A similar phenomenon, described recently and termed micro-
glial process convergence (MPC) involves the convergence of
microglial processes on neuronal dendrites in response to a
reduction of extracellular Ca2þ (Eyo et al., 2015). The induction of
microglial migration, morphological transformation and process
extension towards various pathological signals by P2Y12 receptors
probably represents a protective mechanism which could be
beneﬁcial during early stages of injury. Accordingly, the protective
role of microglial P2Y12 receptors against brain ischemia (Webster
et al., 2013) or LPS induced sepsis (Liverani et al., 2014b) has been
demonstrated. In the case of a more pronounced stroke model,
however, the pro-inﬂammatory action of P2Y12 receptor activation
prevails and pharmacological blockade of the receptor in this case is
protective (Gelosa et al., 2014). In addition to P2Y12 receptor
expression on microglia, oligodendrocytic expression may be an
important marker of demyelinating lesions in the neuro-
inﬂammatory disease, ALS (Amadio et al., 2014).
P2Y13 receptors expressed by cerebellar astrocytes and neurons
confer neuroprotection through the activation of the GSK3 ERK1/2
pathway (Perez-Sen et al., 2015). Finally P2Y14 receptors are also
expressed by microglia, however these receptors are exclusively
sensitive to UDP-glucose and other conjugates of UDP but not
adenine or uracil nucleotides (Bianco et al., 2005). Again, the
participation of P2Y14 receptors in neuroinﬂammation may be
identiﬁed by future studies, as their role in the regulation of cell
stress and repair in the periphery implicate a similar role in the
nervous system (Jacobson et al., 2015).
1.3. The role of adenosine in neuroinﬂammation
Extracellular concentrations of adenosine are regulated by
direct release from cells (Melani et al., 2012), extracellular meta-
bolism of released ATP (Zimmermann, 2000) and reuptake into
cells followed by intracellular metabolism (Bender and Hertz,
1986). Adenosine is principally metabolized in the CNS by adeno-
sine kinase, an enzyme expressed in highest concentrations in as-
trocytes (Studer et al., 2006). Extracellular concentrations ofisms in neuroinﬂammation: An update from molecules to behavior,
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porters expressed on astrocytes (Peng et al., 2005), with adenosine
release, uptake and metabolism forming an ‘adenosine-cycle’,
described in detail by Boison (2008). Following metabolic stress
and cell damage, for example, under conditions of high neuronal
activity or brain injury, the extracellular concentration of adenosine
is dramatically elevated where it acts, in concert with ATP, as an
alarm molecule, promoting or inhibiting neuroinﬂammation,
depending on a host of complex factors, which are only beginning
to be understood.
Cellular responses to extracellular adenosine are co-ordinated
by four different metabotropic P1 receptor subtypes: A1 A2A, A2B
and A3. Of these, the A1 receptor and A3 receptor inhibit the pro-
duction of cAMP, via Gi protein signaling, while the A2A receptor
and A2B receptor increase intracellular concentrations of cAMP via
Gs (Fredholm et al., 2007). As such, these receptors in general act in
opposition to each other and the cellular response depends on the
concentration of receptors expressed, their afﬁnity for adenosine,
activation dynamics, extracellular adenosine concentrations and
other complex factors (Chen et al., 2014). In addition to classical
cAMP-mediated pathways, evidence is accumulating for P1 re-
ceptors operating through alternative signaling systems. Of
particular note, evidence for protein kinase C (PKC), phosphoino-
sitide 3 kinase (PI3K) kinase and mitogen activated protein kinase
(MAPK) involvement in P1-mediated signaling cascades have been
reported (Schulte and Fredholm, 2003). Further, the direct activa-
tion of Kþ channels and inhibition of Ca2þ channels has been re-
ported following A1 receptor activation (Hasko and Pacher, 2008).
While P1 receptor expression in the CNS is dominated by A1 and
A2A, the extent of A2B and A3 receptor expression is contentious, but
as these receptors mediate inﬂammatory responses on immune
effector cells in the periphery (Latini and Pedata, 2001), they may
also play an important role in mediating neuroinﬂammatory pro-
cesses, even at low concentrations. On microglia, van der Putten
et al. reported A1, A2A and A3 receptor expression, but not A2B (van
der Putten et al., 2009), whereas a more recent report revealed the
presence of the A2B receptor onmicroglia, and an important role for
this receptor in augmenting the production of the cytokine, IL-10
(Koscso et al., 2012). The difﬁculty in ascertaining P1 subtype
expression on speciﬁc cell types lies in the possible introduction of
experimental artifacts from cell culture methods, detection limits
associated with anatomical methods and speciﬁcity issues relating
to physiological approaches using pharmacological tools. Never-
theless, the available data collectively suggest that all four receptor
subtypes are expressed on astrocytes, oligodendrocytes and
microglia (Boison, 2012). Evidence also indicates that P1 receptor
expression can be modulated by neuroinﬂammatory conditions
themselves (Orr et al., 2009).
P1 receptors can play a role in inﬂammasome activation through
the classical cAMP-pathway. Chiu et al. reported that, following A2A
receptor activation, Kþ efﬂux is increased via an intracellular
elevation of cAMP and, subsequent protein kinase A (PKA) activa-
tion (Chiu et al., 2014). As described previously, Kþ efﬂux stimulates
the activation of caspase-1 via increases in extracellular Kþ,
decreased intracellular Kþ concentrations, or both (Bernier, 2012).
The relative concentration of Kþ in the intra- and extracellular
compartments appears to be a key point where P2X and P1
signaling converges to modulate inﬂammasome activation (Fig. 1).
Moreover, an increase in extracellular adenosine concentration
stimulates both caspase-1 activity and IL-1b production (Chiu et al.,
2014). As A1 and A3 receptors act in opposition to A2A receptors, it is
likely that the cellular response to high levels of extracellular
adenosine is, to some extent dependent on the ratio of receptors
expressed, however, alternative, non-cAMP-dependent pathways
are also likely to be of importance.Please cite this article in press as: Beamer, E., et al., Purinergic mechan
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ceptor involved in mediating neuroinﬂammation in response to
increases in extracellular concentrations of adenosine, not only via
activation of the inﬂammasome and subsequent increases in IL-1b
production, but also by the recruitment and activation of microglia
and alterations in astrocyte function (Rebola et al., 2011). Microglial
process retraction and activation is of critical importance to the
neuroinﬂammatory response, and P1 receptors are key modulators
of this process. During chronic neuroinﬂammation, process
retraction is mediated by the upregulation of the A2A receptor (Orr
et al., 2009). As an example, a recent study showed that microglial
process retraction in a mouse model of Parkinson's disease is A2A
receptor-dependent (Gyoneva et al., 2014), while Ohsawa et al.
postulate an important role for the A3 receptor in mediating this
process (Ohsawa et al., 2012). Further, A2AR activation on microglia
induces COX-2 expression (Fiebich et al., 1996), an important
marker and mediator of inﬂammation. The effect of microglial A1
receptor activation can be either pro- or anti-inﬂammatory,
depending on other factors in the environment (Hasko et al.,
2005); however, both neuroinﬂammation and microglial activity
is enhanced in an A1A knockout mouse strain under pathological
conditions, suggesting that the primary role of A1A receptor
signaling is anti-inﬂammatory (Luongo et al., 2014).
Astrocytes also play an important role in mediating neuro-
inﬂammation, not least, bymodulating extracellular concentrations
of ATP and adenosine, as previously discussed. P1 receptors
expressed on astrocytes are vital components in mediating this
process. In addition, pharmacological A2A receptor blockade
inhibited astrogliosis in primary astroglial cultures (Brambilla et al.,
2003). Because astrocytes are responsible for the maintenance of
adenosine concentrations in the extracellular environment,
through adenosine kinase, astrogliosis can lead to a decrease in
extracellular adenosine. Fedele et al. (2005) demonstrated that
astrogliosis contributes to ictogenesis via an ADK-dependent
increased removal of adenosine from the extracellular space.
Whether increased extracellular adenosine concentrations have
a pro- or anti-inﬂammatory effect is unclear, and appears to be
dependent on other variables, such as relative expression of
different P1 receptors. Hindley et al. report that direct cortical in-
jections of an adenosine analog 5'-(N-cyclopropyl)-carbox-
amidoadenosine, triggered reactive gliosis, which could be
reversed with A2 receptor blockade, suggesting the primary effect
of high extracellular adenosine concentrations in the CNS is
proinﬂammatory and mediated by A2A receptor activation (Hindley
et al., 1994). Another study, however, report that speciﬁc A3 ago-
nists provide neuroprotection against ischemia (Choi et al., 2011).
The effect of glial activation on neuroinﬂammation and neuronal
cell fate is likely to depend on speciﬁc conditions. A2A receptor
agonists reduce long-term neurologic injury after blunt spinal
trauma (Reece et al., 2004), while a similar treatment improves
recovery following experimental stroke (Pedata et al., 2014), in
contrast to reports of the proinﬂammatory action of this receptor.
In summary, the role of adenosine in mediating neuro-
inﬂammation is multi-factorial, involving activation of the
inﬂammasome and the recruitment and activation of astrocytes
and microglia. The A1 receptor and A3 receptor act in opposition
to the A2A and A2B receptor in cAMP-mediated pathways, which
are sufﬁcient to explain much of the cellular response. The net
effect of increased extracellular adenosine however is dependent
on pathology, adenosine concentrations, receptor expression and
cross-talk with pathways mediated by ATP and other signaling
molecules. Conﬂicting reports of whether adenosine is pro- or
anti-inﬂammatory underscore the complexity of this molecule's
role in mediating neuroinﬂammatory cascades (Liang et al.,
2014).isms in neuroinﬂammation: An update from molecules to behavior,
.09.019
E. Beamer et al. / Neuropharmacology xxx (2015) 1e11 71.4. Purinergic regulation of neuroinﬂammation in CNS disorders
The role of purinergic receptors has been implicated in the
majority of CNS diseases, characterized or accompanied by neuro-
inﬂammation. Because purinergic signaling in various neurode-
generative diseases are discussed in detail elsewhere in this issue
(Burnstock, 2015), we focus here on non-organic psychiatric dis-
orders, which are also coupled to inﬂammation and the repair
process. Neuroimmunological alterations appear in classical psy-
chiatric disorders, such as major depressive disorder (MDD), bi-
polar disorder (BD), obsessive compulsive disorder (OCD) and
schizophrenia. Medical conditions associated with chronic
inﬂammation, such as diabetes, obesity, or autoimmune diseases
share comorbidity or increase the risk of psychiatric disorders, such
as MDD. In contrast to neurodegenerative diseases, however, these
disorders are characterized by chronic, low grade or intermittent
inﬂammation, rather than a robust acute inﬂammation in the brain
parenchyma, which is present e.g. after stroke or seizures.
As a reﬂection of inﬂammation in the peripheral blood, many
human studies have revealed an altered innate immune status and
cytokine proﬁle in patients suffering from major depression and
schizophrenia. For instance, a recent meta-analysis collecting data
from 29 individual studies reported that serum IL-2 receptor, IL-6
and tumor necrosis factor-a (TNF-a) levels are elevated in MDD
patients (Liu et al., 2012; Najjar et al., 2013). Among these, IL-6 and
TNF-a, correlatewith exacerbation and normalization of depressive
episodes and the risk of suicide attempts, and are therefore pro-
posed to not only be trait but also state markers of the disorders
(Janelidze et al., 2011). This molecular proﬁle is consistent with a
Th1-proinﬂammatory immunophenotype. In contrast to acute
neuroinﬂammatory conditions in MDD, however, astroglia and
microglia do not proliferate (Najjar et al., 2013), consistent with a
continuous, low grade inﬂammation. As for BPD, peripheral IL-2, IL-
4 and IL-6 are found to be increased in manic episodes (Brietzke
et al., 2011) whereas another meta-analysis revealed signiﬁcant
elevation of soluble interleukin (IL)-2 receptor (sIL-2R), TNF-a,
soluble tumor necrosis factor receptor type 1 (sTNFR1) and soluble
interleukin (IL)-6 receptor (sIL-6R) (Munkholm et al., 2013). In the
case of schizophrenia, TNF-a, IFN-g, IL-12 and IL-2 are consistently
elevated in chronic schizophrenic patients, while IL-1b, IL-6 and
TGF-b correlate positively with disease activity (Miller et al., 2011).
Schizophrenia is also regarded as a neurodevelopmental disor-
der, and fetal neuroinﬂammation, which could be the consequence
of maternal infection (Meyer, 2013), is implicated in its etiology.
Fetal neuroinﬂammation is characterized by enhanced levels of
proinﬂammatory cytokines in the brain and enhanced microglial
activation, which changes neurodevelopmental trajectories and
thereby predisposes the developing brain to long-term pathology,
which is later manifested, during adolescence. During the postnatal
period, further postnatal stressors can induce or maintain neuro-
inﬂammation during development leading to abnormal brain
maturation and behavioral changes in the prodromal period, which
eventually develop into an overt psychosis. Because purinergic
mechanisms, in particular P2X7 receptors, regulate many aspects of
neuroinﬂammation, it is unsurprising that emerging evidence in-
dicates their activation and participation in animal models of psy-
chiatric disorders.
In rodent studies mimicking depressive-like behaviors, both
genetic deletion and pharmacological inhibition of P2X7 receptors
lead to an antidepressant phenotype, which is manifested in the
widely used forced swim (FST) and tail suspension tests (TST)
(Basso et al., 2009; Boucher et al., 2011; Csolle et al., 2013a,b;
Pereira et al., 2013; Wilkinson et al., 2014), but can also be
measured using more complex paradigms such as learned help-
lessness (Iwata et al., 2013). Acute stress induced depressiveelikePlease cite this article in press as: Beamer, E., et al., Purinergic mechan
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ceptor antagonism, (Csolle et al., 2013b; Ma et al., 2014). When
footshocks were used as a stressor, however, no change in behavior
was found in the presence of a P2X7 antagonist (Catanzaro et al.,
2014). Conﬂicting results were obtained using chronic stress
models: chronic restraint leads to a downregulation of P2X7 mRNA
throughout the hippocampus (Kongsui et al., 2014), whereas
another study found a markedly upregulated Cx43 and Panx1
opening in the hippocampus under similar conditions, mediated by
NMDA/P2X7 receptor signaling (Orellana et al., 2015). Interestingly,
a very recent study of the same group revealed that a similar
upregulation of the Cx43 and Panx1 pathway can be detected in
offspring in response to maternal LPS treatment (Avendano et al.,
2015).
Interestingly, ATP alone also elicits a rapid antidepressant-like
effect if added directly to the CNS in the chronic social defeat
model of depression, an effect probably mediated by P2X2 re-
ceptors in the medial prefrontal cortex (Cao et al., 2013). To study
the manic pole of bipolar disorder, genetic deﬁciency and phar-
macological blockade of P2X7 receptors attenuated hyperactivity
induced by amphetamine in all studies examined (Bhattacharya
et al., 2013; Csolle et al., 2013a; Gubert et al., 2014; Lord et al.,
2014). These ﬁndings indicate that the presence and endogenous
activation of P2X7 receptors contributes to behavioral changes
induced by either negative or positive challenges, and the blockade
of the receptor alleviates these ﬂuctuations.
Several attempts have been made to correlate behavioral
changes with neuroinﬂammatory parameters, in particular with IL-
1b levels in the CNS and periphery, given the well-established role
of P2X7s in the regulation of posttranslational processing of this
cytokine. However, it appears that the scenario is more complex as
only LPS-induced, but not the basal IL-1b levels are subject to
regulation by P2X7 receptors in the rodent brain (Csolle and
Sperlagh, 2010; Mingam et al., 2008) and the mood stabilizing
phenotype detected in the absence of P2X7 receptors was not
transferredwith bonemarrow transplantation (Csolle et al., 2013b).
The contribution of P2X7 receptors present on cells of hemato-
poietic origin such as peripheral immune cells to behavioral
changes detected in naïve animals, therefore, seems minimal.
Rather, P2X7-regulated intrinsic neuronal mechanisms such as
the modulation of glutamatergic neurotransmission (Csolle et al.,
2013b) or nitric oxide signaling (Pereira et al., 2013) may repre-
sent the underlying mechanisms of the antidepressant phenotype.
On the other hand, amphetamine induced induction of IL-1b and
oxidative stress (Gubert et al., 2014) in the striatum were reversed
by a P2X7 receptor antagonist coincidently with the alleviation of
amphetamine induced behavior and amphetamine induced striatal
dopamine release is attenuated by the P2X7 receptor deﬁcient
genotype (Csolle et al., 2013a). The lack of local IL-1b induction and
subsequent modulation of dopamine release in the absence of P2X7
receptor could explain the alleviation of amphetamine induced
hyperlocomotion. Interestingly, ATP-induced cell death in the hip-
pocampus e a process probably mediated by P2X7 receptors ewas
reversed by the mood stabilizer drugs lithium and valproate (Wilot
et al., 2007), therefore the action of currently used drugs against
bipolar disorder might also involve P2X7 receptors.
Although less data have been accumulated, a recent study
suggests that P2X7 receptors also regulate social behavior, an
important aspect of psychiatric disorders. While JNJ-42253432, a
novel brain-penetrant P2X7 receptor antagonist, did not affect
footshock induced decreases in social interactions, it elicited a
robust increase in overall social activity (Lord et al., 2014). There-
fore, P2X7 receptor modulation may represent an intriguing pos-
sibility for interfering with neuropsychiatric conditions
characterized by social deﬁcit (e.g. schizophrenia, autism). Inisms in neuroinﬂammation: An update from molecules to behavior,
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identiﬁed yet, a line of recent studies found that suramin, a broad
spectrum purinergic antagonist, attenuates the whole variety of
neurobiological and phenotypic alterations in different animals
models of autism spectrum disorder, including the poly(I:C) model
representing maternal immune activation (Naviaux et al., 2014,
2015, 2013).
Finally the neuroinﬂammatory response evoked by the recrea-
tional drug 3,4 emethylenedioxymethamphetamine (MDMA,
ectasy) also appear to involve the activation of P2X7 receptor:
MDMA-induced BBB leakage, subsequent microglial activation and
metalloproteinase induction were suppressed by in vivo treatment
with speciﬁc P2X7 receptor antagonists (Rubio-Araiz et al., 2014).
Apart from the nucleotide-sensitive receptors detailed above,
the role of adenosine receptors have also been examined in animal
models of psychiatric disorders, although adenosine mediated
control of neuroinﬂammatory mechanisms has not been envisaged
in this respect. Adenosine has been reported to have an
antidepressant-like effect in the forced swim paradigm, and this
effect has been attributed to the activation of both A1 and A2A re-
ceptors (Kaster et al., 2004) and the subsequent involvement of Kþ
conductances (Kaster et al., 2007a) and the endogenous opioidergic
system (Kaster et al., 2007b). Orally administered inosine also re-
produces this effect (Muto et al., 2014). Interestingly A2A receptor
gene deﬁciency and A2A receptor antagonists, including caffeine,
also have antidepressant-like effect in the FST and TST (El Yacoubi
et al., 2003; Hodgson et al., 2009) as well as in the chronic unpre-
dictable stress paradigm of depression (Pechlivanova et al., 2012).
The antidepressant effect of A2A antagonists are most likely
mediated by D2 receptors in the ventral striatum (El Yacoubi et al.,
2003). More recently, it was found that the rapid antidepressant-
like effect of sleep deprivation is mediated by astrocyte-derived
adenosine as it is absent in A1 receptor knockout and astrocyte-
deﬁcient dnSNARE mice and can be mimicked by CCPA, an A1-se-
lective agonist (Hines et al., 2013). Further, astrocyte-speciﬁc
deletion of A2A receptors mimics certain features of the schizo-
phrenia endophenotype, such as decreased working memory and
enhanced psychomotor response to the NMDA antagonist MK-801
(Matos et al., 2015). These data point to the role glia-neuron cross
talk in the action of endogenous adenosine on behavior. A poten-
tially fruitful area of further investigation could be the identiﬁca-
tion of a link between the impact of adenosine receptors on
neuroinﬂammatory mechanisms and its role in neuropsychiatric
disorders.
The assumption underlying most research involving the role of
purinergic signaling in neuroinﬂammation is that inﬂammatory
responses exacerbate injury. However, the complex pathways
leading to inﬂammasome activation are highly conserved, sug-
gesting a strong adaptive value. It is likely, therefore, that reducing
neuroinﬂammation associated with pathology is not necessarily
always of value. Roth et al. (2014) investigated the role of purinergic
signaling in neuroinﬂammatory responses following TBI and found
that the P2X7-mediated inﬂammatory response contributes to
better outcomes, with activated microglia protecting the paren-
chyma and myelomonocytic cells invading the damaged meninges.
Both purinergic mechanisms and reactive oxygen species are key
players in the response to injury. In this study, these pathways
could be manipulated by delivering pharmacological agents
transcranially.
2. Conclusion
Purines are ubiquitous extracellular mediators, which are
released to the extracellular space under conditions of inﬂamma-
tion. Among various subtypes of purinergic receptors, both P1 andPlease cite this article in press as: Beamer, E., et al., Purinergic mechan
Neuropharmacology (2015), http://dx.doi.org/10.1016/j.neuropharm.2015P2 receptors participate in the regulation of the inﬂammatory
response of the CNS in a complex way, i.e. in the activation of the
inﬂammasome, the synthesis and posttranslational processing of
IL-1b and other pro- and anti-inﬂammatory cytokines, the
recruitment and activation of microglia and in reactive astrogliosis.
Under pathological conditions purinergic receptors are up-/or
downregulated, and therefore the contribution of purinergic
regulation dynamically changes during acute and chronic phases of
neuroinﬂammation.
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